Gut Check: Are Advanced Tests Helping or Hurting IBD Patients?
"A closer look at how multiplex gastrointestinal pathogen panels (GPPs) impact outcomes for individuals with inflammatory bowel disease (IBD)."
Living with inflammatory bowel disease (IBD) means navigating a constant balancing act. Is that abdominal pain a flare-up of your condition, or something else entirely? Gastrointestinal infections can mimic IBD symptoms, making it crucial to identify the true culprit. Traditionally, doctors have relied on stool cultures and specific tests for Clostridium difficile (C. difficile) to diagnose infections in IBD patients. However, a new generation of tests called multiplex gastrointestinal pathogen panels (GPPs) has emerged, promising faster and more comprehensive results. But are these advanced tests truly better for IBD patients?
GPPs detect a wide array of bacteria, viruses, and parasites by identifying their genetic material. They offer several advantages over traditional methods, including speed and the ability to detect multiple pathogens simultaneously. However, GPPs are so sensitive that they can pick up non-viable organisms or remnant genetic material, leading to the detection of pathogens that aren't actually causing illness. This oversensitivity raises concerns about misdiagnosis, unnecessary antibiotic use, and delays in appropriate IBD treatment.
A recent study delved into the real-world impact of GPPs on IBD patients experiencing suspected flare-ups. Researchers compared outcomes for patients who underwent GPP testing versus those who had traditional stool testing. The findings might surprise you.
Testing at the Front Line: Blood, Stool, and Antibody Panels
Diagnosis of IBD typically begins with blood and stool laboratory tests before more invasive procedures. Serologic antibody tests such as ASCA are sometimes used, but a negative result does not rule out Crohn's disease, ulcerative colitis, or another form of IBD. The presence of multiple antibodies, such as ASCA, anti-CBir1, and anti-OmpC, may indicate a likelihood of more aggressive disease, though negative results do not rule out aggressive disease. Treatment reflects severity, with anti-inflammatory medicines often the first step in treating ulcerative colitis, typically for mild to moderate disease. Experts also draw an important distinction between diagnostic testing and prognostic testing aimed at predicting how the disease will behave.
What the Standard Approach Actually Measures
Inflammatory bowel disease is characterized by chronic inflammation in the digestive tract, with ulcerative colitis and Crohn's disease as the two main types. Both conditions are chronic inflammatory disorders of the gastrointestinal tract that persist over time. Standard diagnosis therefore centers on identifying and characterizing this inflammation, typically distinguishing Crohn's disease from ulcerative colitis before therapy is selected.
From Endoscopy to the Genome
The IBD diagnosis journey has long relied on a standard suite of procedures, including blood tests, stool tests, endoscopy, colonoscopy, and imaging techniques. In recent decades, findings from IBD genome-wide association studies have begun to be translated into clinical prognostic and diagnostic indicators of disease. However, patient perception and understanding of these tests and their utility remain important considerations. How well patients grasp what genetic tests measure influences how the results are used and interpreted in clinical care.
The GPP Paradox: More Information, Worse Outcomes?
The study, published in Digestive Diseases and Sciences, included 268 IBD patients who underwent stool testing for suspected flares between 2012 and 2016. Half of the patients received GPP testing, while the other half underwent conventional stool culture and C. difficile testing. The researchers then compared several outcomes, including hospitalization rates, emergency department (ED) visits, and IBD treatment modifications.
- Higher healthcare utilization: Patients in the GPP group had three times higher odds of IBD-related hospitalization, surgery, or ED visits within 30 days of testing.
- Less IBD treatment modification: Patients in the GPP group were less likely to have their IBD medications adjusted in response to the test results.
New Assays and Where Testing Is Headed
IBD, which includes Crohn's disease and ulcerative colitis, affects the intestines, and diagnosis typically draws on laboratory tests, endoscopy, and imaging. Researchers continue to develop new diagnostic tools, including an optical assay built around a granzyme A (GzmA) reporter. The reporter was tested on samples from 150 individuals with and without IBD, and results showed that combining the GzmA reporter with standard calprotectin testing improved the ability to identify IBD compared with calprotectin alone. Such combinations point toward assays that could enhance both diagnosis and ongoing monitoring.
Where Advanced Testing Earns Its Keep
Even as advanced tests multiply, accurate diagnosis remains the key to guiding therapy, particularly for patients with suspected monogenic early-onset IBD. Mayo Clinic Laboratories' gastroenterology test panel, explained by Ann Moyer, M.D., Ph.D., is designed to provide a comprehensive evaluation of patients with this condition. The focus on early-onset, monogenic disease highlights where advanced genetic testing can meaningfully change clinical decisions, while also underscoring that such testing targets a specific subgroup rather than the broader IBD population.
IBD vs. IBS: Why the Distinction Matters
Irritable bowel syndrome and inflammatory bowel disease sound similar, but they are actually two very different health conditions with equally different treatment options. IBS is a functional gastrointestinal disorder, meaning the digestive tract looks normal on testing but does not function properly. IBD, by contrast, involves chronic inflammation in the digestive tract. Because the underlying problems differ so fundamentally, the tests and treatments used for each condition diverge as well.
Rethinking the Approach to Infections in IBD
This study highlights the importance of carefully considering the implications of new diagnostic technologies. While GPPs offer the allure of comprehensive pathogen detection, they may not always be the best choice for IBD patients. In some cases, sticking with traditional C. difficile testing may be the most prudent approach. When GPPs are used, it's crucial for healthcare providers, especially those less specialized in IBD, to interpret the results cautiously and avoid reflexively prescribing antibiotics for every detected pathogen. A more nuanced approach, focusing on the patient's overall clinical picture and considering the possibility of an IBD flare, is essential to ensure the best possible outcomes.
Diagnostic Versus Prognostic Testing
Expert discussion of IBD testing distinguishes the diagnostic tests used to diagnose and monitor the disease from prognostic testing aimed at predicting future complications. Understanding the common diagnostic tests is central to patient care, but the goals and challenges of predicting complications through prognostic testing remain an active area of discussion. Forecasting which patients will develop complications is considerably harder than confirming the presence of disease. This distinction matters for patients weighing whether additional or more advanced tests will actually change their care.
Where Research Is Heading Next
Research into IBD continues to advance across diagnostics, treatments, and frontiers of research. Where new diagnostic capacity is most needed is shaped by global disease trends, including hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries. A population-based study of countries in the Organisation for Economic Co-operation and Development, published in The Lancet Gastroenterology & Hepatology, examined these trends. Shifting patterns of hospitalisation in newly industrialized countries will likely influence where diagnostic advances deliver the greatest benefit.
Colonoscopy Overuse, Children, and Pregnancy
One systemic challenge in IBD care is over-reliance on invasive procedures. A new testing protocol featuring serial home tests was found in a study to reduce unnecessary colonoscopies for suspected IBD patients, potentially speeding up diagnosis. Testing must also accommodate different patient populations: educational materials explain what tests are common for children with IBD, and clinical guidance addresses testing during pregnancy alongside fertility, delivery, and breastfeeding considerations. Taken together, these examples show that the real-world impact of testing depends on who is being tested and whether protocols are streamlined.
What Happens Outside the Clinical Trial
Behind the statistics are individual patients switching between therapies, often with little real-world evidence to guide them. Data on starting intravenous (IV) vedolizumab and transitioning to subcutaneous (SC) treatment in IBD are scarce, according to researchers studying real-world outcomes. Because most evidence comes from controlled trials rather than everyday practice, patients and clinicians are left with limited information about how these transitions actually play out outside the research setting. Studies that capture real-world outcomes aim to close that gap and reflect the human experience of IBD treatment.